Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $24.88 million. The enterprise value is $249.48 million.
| Market Cap | 24.88M |
| Enterprise Value | 249.48M |
Important Dates
The last earnings date was Monday, September 14, 2026, after market close.
| Earnings Date | Sep 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 63.48 million shares outstanding. The number of shares has increased by 1.27% in one year.
| Current Share Class | 63.48M |
| Shares Outstanding | 63.48M |
| Shares Change (YoY) | +1.27% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 6.30% |
| Float | 44.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.10 |
| Forward PS | n/a |
| PB Ratio | 0.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 0.31 |
| P/OCF Ratio | 0.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.62, with an EV/FCF ratio of 3.14.
| EV / Earnings | n/a |
| EV / Sales | 1.05 |
| EV / EBITDA | 15.62 |
| EV / EBIT | n/a |
| EV / FCF | 3.14 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 3.69.
| Current Ratio | 0.81 |
| Quick Ratio | 0.46 |
| Debt / Equity | 3.69 |
| Debt / EBITDA | 14.83 |
| Debt / FCF | 2.98 |
| Interest Coverage | -0.01 |
Financial Efficiency
Return on equity (ROE) is -28.05% and return on invested capital (ROIC) is -0.16%.
| Return on Equity (ROE) | -28.05% |
| Return on Assets (ROA) | -0.05% |
| Return on Invested Capital (ROIC) | -0.16% |
| Return on Capital Employed (ROCE) | -0.24% |
| Weighted Average Cost of Capital (WACC) | 16.00% |
| Revenue Per Employee | $316,644 |
| Profits Per Employee | -$62,450 |
| Employee Count | 751 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, BIOX has paid $3.40 million in taxes.
| Income Tax | 3.40M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.80% in the last 52 weeks. The beta is 0.43, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -76.80% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.62 |
| Relative Strength Index (RSI) | 48.35 |
| Average Volume (20 Days) | 555,625 |
Short Selling Information
The latest short interest is 327,738, so 0.52% of the outstanding shares have been sold short.
| Short Interest | 327,738 |
| Short Previous Month | 913,482 |
| Short % of Shares Out | 0.52% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 0.73 |
Income Statement
In the last 12 months, BIOX had revenue of $237.80 million and -$46.90 million in losses. Loss per share was -$0.74.
| Revenue | 237.80M |
| Gross Profit | 82.50M |
| Operating Income | -500,000 |
| Pretax Income | -47.00M |
| Net Income | -46.90M |
| EBITDA | 15.97M |
| EBIT | -500,000 |
| Loss Per Share | -$0.74 |
Balance Sheet
The company has $12.20 million in cash and $236.80 million in debt, with a net cash position of -$224.60 million or -$3.54 per share.
| Cash & Cash Equivalents | 12.20M |
| Total Debt | 236.80M |
| Net Cash | -224.60M |
| Net Cash Per Share | -$3.54 |
| Equity (Book Value) | 64.10M |
| Book Value Per Share | 0.61 |
| Working Capital | -51.80M |
Cash Flow
In the last 12 months, operating cash flow was $81.87 million and capital expenditures -$2.37 million, giving a free cash flow of $79.50 million.
| Operating Cash Flow | 81.87M |
| Capital Expenditures | -2.37M |
| Depreciation & Amortization | 16.47M |
| Net Borrowing | -68.73M |
| Free Cash Flow | 79.50M |
| FCF Per Share | $1.25 |
Margins
Gross margin is 34.69%, with operating and profit margins of -0.21% and -19.72%.
| Gross Margin | 34.69% |
| Operating Margin | -0.21% |
| Pretax Margin | -19.76% |
| Profit Margin | -19.72% |
| EBITDA Margin | 6.72% |
| EBIT Margin | -0.21% |
| FCF Margin | 28.74% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.27% |
| Shareholder Yield | -1.27% |
| Earnings Yield | -188.48% |
| FCF Yield | 319.50% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 34.55% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |